Compare Novo Nordisk A/S (NVO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Williams-Sonoma, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Williams-Sonoma, Inc. trades at $223.2 (market cap $26.30B). The key difference: Novo Nordisk A/S is far larger — about 8.4× Williams-Sonoma, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | WSM | |
|---|---|---|
Market Cap | $220.53B | $26.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $240.06 |
52-Week Low | $35.29 | $168.64 |
Enterprise Value | $239.49B | $27.14B |
Dividend Yield | 3.63% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Williams-Sonoma (WSM) trades at $221.13, down 3.19% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has shown volatility. Recent earnings beats and consistent dividend payments highlight operational strength amid consumer discretionary sector challenges noted in recent financial media coverage.
The outlook is mixed with solid fundamentals and analyst consensus near current price, but risks include consumer spending sensitivity and competitive pressures. Upside potential exists if earnings momentum continues, yet macroeconomic headwinds and sector underperformance pose near-term challenges for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
